PeptidePedia The community reference

Wuhan Wansheng Biotechnology (revision 65)

Old revision·03:22, 11 Nov 2025·StubSorterBot

This is an old revision of this page, as it stood at 03:22, 11 Nov 2025, saved by StubSorterBot with the summary bot: update parent category chain. It may differ substantially from the current revision, and any error it contains may since have been corrected.
This article is about the organisation. For the general subject, see Peptide supply chain; for the criteria under which supplier articles exist here, see Project:Vendor notability.
This article relies excessively on primary sources. (July 2026) Discussion: RfC: does a large report set support any conclusion?.
Wuhan Wansheng Biotechnology Co., Ltd.Organisation
representative synthesis and QC site (schematic)
Schematic synthesis and quality-control site. No image of this organisation's premises is available to this wiki.
Legal nameWuhan Wansheng Biotechnology Co., Ltd.
Trading nameWWB
Other designationsWansheng Bio, WWBT
Identity
FoundedNot documented
HeadquartersWuhan, Hubei, China
IndustryResearch-compound supply
Shop domainVisit WWB
Products and documentation
Product scopepeptides, SARMs, injectable materials and raw materials
Catalogue sizeNot documented
DocumentationBatch certificate of analysis reported with orders
Independent reportsSubmitted to this wiki by purchasers; see §Independent testing record
PeptidePedia reception tally
Submissions914 to July 2026
Evidence qualityWeak — self-selected, self-reported
Organisation infobox · conventions

Wuhan Wansheng Biotechnology Co., Ltd. (trading as WWB; wuhanwanshengbio.com) is a research-compound supplier based in Wuhan, Hubei, China, supplying research peptides, SARMs and raw materials, and notable for having one of the largest published third-party test-report sets of any organisation covered on this wiki.[1][2]

The organisation is one of twenty covered on PeptidePedia under Project:Vendor notability. Like the others, it distributes material labelled for research use only, which is not approved for human use in any major jurisdiction and is not manufactured under the quality obligations that apply to medicines.[3]

This article describes what is verifiable. Where a statement rests on the organisation's own material it is attributed as such; where it rests on purchaser-submitted test reports the limitations of that evidence are stated; and where it rests on PeptidePedia's own reception tally it is labelled weak, self-reported evidence. Independent testing referred to throughout is that published by Janoshik Analytical, Medutest, PeptideMeter and VendorInvestigate.[4]

Corporate identity and history

[edit]

The organisation operates from Wuhan, Hubei. Neither an incorporation year nor a primary trading domain is documented in sources available to this wiki, and the article does not supply either: an unverified founding year is worse than a blank, because a reader cannot tell one from a verified one.[1]

What distinguishes the organisation is the size of its published testing record. A body of several hundred third-party reports has been associated with its material, which is a substantially larger set than for any other entity covered here.[5] That volume is the strongest element of its notability case, and it is also the subject of the longest-running dispute on this talk page — because a large number of reports is not the same as a good testing record, and the article has to be careful not to let the first imply the second.

Distribution and dispatch

[edit]

The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.

Operations and documentation practice

[edit]

Purchaser reports describe vialled lyophilised material with a batch certificate. Reported certificate content has been variable, and the variance is wider than for most entities covered here — some reports describe purity, water and method, others a single purity line.[5]

No incorporation record, certification or facility description is corroborated by any source available to this wiki, and the article makes no statement about any of them.[2]

Product range

[edit]
ClassRepresentative listingsDocumentation reported
Incretin analoguesSemaglutide, tirzepatide, retatrutideCertificate, content varies widely
Research peptidesRepair, secretagogue, cosmetic peptidesCertificate, content varies
SARMsBulk and capsuledCertificate, purity
Injectable and raw materialsBulkCertificate, limited detail

The catalogue is broad and the documentation inconsistent across it — an unusual combination, and one that makes generalisation from any single order unsafe.[5]

Independent testing record

[edit]

The report set associated with this organisation is the largest on the wiki, with several hundred third-party reports across a wide range of analytes.[5] Reported area percent figures span a wider range than for most entities covered here, with the majority in the high nineties and a visible tail below.

What that tail means is genuinely contested. A large report set will contain more low results than a small one simply by being larger, and a set assembled from purchaser submissions is self-selected in ways that may over- or under-represent poor outcomes: a purchaser who suspects a problem is more likely to test, and a purchaser with a good result is more likely to publish. Neither bias has been quantified, and the article does not claim to know the net direction.[5][4]

The one statement the set does support is comparative in a limited way: the dispersion of reported figures is wider here than for entities with more standardised certificates. Dispersion is a property of the reports and not necessarily of the material.[6]

Reception

[edit]

The PeptidePedia tally records 914 self-reported submissions to July 2026 — toward the lower end among the supplier articles. Recurring positive themes are catalogue breadth, price and the availability of testing data; recurring complaints concern documentation inconsistency and variance between orders.[4] Self-selected; reception rather than quality.[4]

How this tally should be read

[edit]

The reception figure above is a mean of self-reported submissions to PeptidePedia. It is weak evidence and is subject to three limitations that apply to every such figure on this wiki:

  • Self-selection. People who submit are not a sample of purchasers. Both satisfaction and dissatisfaction motivate reporting, in unknown proportions.
  • It measures reception, not quality. Packaging, communication and delivery are more visible to a purchaser than purity, and weigh accordingly.
  • It is not comparable across communities. Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.[4]

PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.[4]

[edit]

The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.[1]

Material labelled for research use only is outside the regulatory framework that governs medicines. Its identity, purity, sterility and endotoxin content are not assured by any regulator, and a certificate of analysis issued by a supplier is a claim by that supplier rather than an independent finding.[3][6]

Import of such material for personal use is unlawful or restricted in many jurisdictions, and seizure is a documented outcome. PeptidePedia describes the legal position and does not advise on it.[3]

Notability and coverage

[edit]

This article exists because the organisation satisfies at least three of the five criteria at Project:Vendor notability. The available documentary base is: a company registration record; the organisation's own published material, usable only for what it states about itself; and third-party test reports submitted by purchasers.[1][2][5]

What is not available is independent coverage in a source unconnected with the organisation or its customers. That gap is characteristic of the sector rather than of this entity, and it constrains what a neutral article can say: capability, capacity, manufacturing arrangements and quality systems are not established here, and statements about them appear only as attributed claims.[2]

Two frameworks are named in this article only to say what has not been established against them: a quality-system claim is not a fact until assessed against the applicable good-manufacturing-practice framework,[7] and a testing laboratory's competence is a matter of accreditation to a recognised standard rather than of self-description.[8] Neither assessment is available here for this organisation or for any other covered on this wiki.

[edit]

See also

References

  1. ^ a b c d National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.
  2. ^ a b c d Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per Project:Verifiability.
  3. ^ a b c Research-use-only labelling practice; see Research use only for the legal and commercial function of the phrase.
  4. ^ a b c d e f PeptidePedia reception tally (self-reported submissions; weak evidence — see Project:Sourcing guidelines). Self-selected sample; period and count stated at each point of use.
  5. ^ a b c d e f Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See Blind sampling.
  6. ^ a b United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.
  7. ^ World Health Organization, Good Manufacturing Practices for Pharmaceutical Products: Main Principles, WHO Technical Report Series. The general framework against which a GMP claim is assessed.
  8. ^ ISO/IEC 17025:2017, General requirements for the competence of testing and calibration laboratories. International Organization for Standardization.

Further reading